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terms in the treatment selection equation and the TED equation
proved to be independent we re-estimated by univariate probit.
Sensitivity analyses estimating the effect of olanzapine, risperi-
done and quetiapine independently versus TAP were also con-
ducted. RESULTS: A Wald test of the correlation coefﬁcient of
the disturbances suggests that treatment selection is exogenous
in our model (rho = −0.049 (p = 0.57)) using a Huber-White
sandwich estimator of the variance. The univariate probit para-
meter estimates of AAP is statistically signiﬁcantly positive (p =
0.044) suggesting that AAP are associated with an increased risk
of TED relative to TAP. The marginal effect of AAP is 0.0827;
that is the TED propensity of AAP is 8.27% higher than that of
TAP. A univariate probit model demonstrated that olanzapine (p
= 0.10), quetiapine (p = 0.10) and risperidone (p = 0.31) were
independently associated with an increased risk of TED, though
not signiﬁcantly. A bivariate probit model omitting prior comor-
bidity, drug use and quarterly dummy variables demonstrates
selection bias (rho = −0.650 (p = 0.0029)). CONCLUSION: The
results of this study show that AAP are associated with an
increased risk of TED relative to TAP. Evidence of unobserved
selection bias was not present. Explanatory variables that may
explain treatment selection that were included in our model were
sufﬁcient to control for choice of therapy.
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OBJECTIVES: The association between suicidality and antide-
pressant use has been reported in literature using clinical trial
data. This study 1) investigates the relationship between suici-
dality and antidepressants use in children and adolescents using
managed care claims data; 2) examines the effect of an FDA
black box warning on antidepressant use in children and ado-
lescents. METHODS: Subjects 5–19 years old, continuously
enrolled in a large Midwestern IPA model health plan, diagnosed
with depression (using ICD-9-CM codes) or issued at least one
antidepressant prescription between January 1, 2004 and June
30, 2005 were included in the study. Descriptive statistics, paired
samples t-test, Chi-Square test, and stepwise logistic regression
were used to analyze the data. RESULTS: A total of 5104 sub-
jects (7.2% continuously enrolled in 5–19 year olds) met the
study criteria; 53% female; mean age was 15 years; 67% had
depression diagnosis. Antidepressant use was modestly associ-
ated with suicidality using Chi-square test (x2 = 3.03, p = 0.08;
contingency odds ratio = 1.67). Logistic regression showed that
antidepressant use is not a signiﬁcant predictor to suicidality,
while gender, depression diagnosis, other comorbid mental
health, drug and alcohol abuse, and specialty provider were sig-
niﬁcant predictors to suicidality. While average days on antide-
pressant drug therapy decreased signiﬁcantly (p = 0.009) after
the black box warning, the number of inpatient stays for depres-
sion after the black box warning increased signiﬁcantly (p =
0.007). CONCLUSION: From this claims database, the associ-
ation between suicidality and antidepressant use in children and
adolescents is not clear. Caution is needed in the use of antide-
pressants in this population. Increased inpatient stays following
the black box warning may be an indication that providers are
more aware of the suicidality risk or due to decreased use of anti-
depressants. It is important to balance appropriate usage and
concerns for the safety of medications with the risk of adverse
events and subsequent health service use.
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OBJECTIVES: Depression is the most prevalent major mental
health disorder, affecting between eight and ten percent of the
U.S. population. The U.S. Medicaid programs spent approxi-
mately $2 billion on antidepressant drugs in 2005, across three
categories of antidepressants including selective serotonin reup-
take inhibitors, tricyclic antidepressants, and other antidepres-
sants. Predicting future prices and utilization of antidepressants
would facilitate Medicaid’s planning process. Our objective is to
build forecasting models that can be used to improve Medicaid’s
budgeting efforts. METHODS: We gather quarterly data
(1991–2004, Centers for Medicare & Medicaid Services) on
Medicaid national antidepressant expenditure. We use Box-
Jenkins forecasting techniques on expenditure and utilization
time series for speciﬁc antidepressants including Paxil, Prozac,
Wellbutrin and Zoloft. Intervention analysis is used to determine
the effects of patent expiration, new branded-drug entry, and
new indication approval. Forecasts are computed and compared
to a holdout sample, comprised of the 2005 data, to assess the
performance of the models. RESULTS: The Box-Jenkins ARIMA
algorithms for ﬁtting and diagnosing the expenditure and uti-
lization data resulted in four distinct non-stationary forecasting
models. Final models were selected using standard information-
based criteria. The Paxil and Prozac models incorporated an
intervention term corresponding to patent expiration: a step
function for Paxil and an exponential decay for Prozac. The best
ﬁtting model for Wellbutrin is a third order moving average in
the ﬁrst differences; the Zoloft model is a Random Walk.
Maximum likelihood was used for estimations. Usual checks on
the residuals proved to be satisfactory. CONCLUSION: ARIMA
modeling can be used to capture the time series of individual
antidepressant drugs purchased by Medicaid. Moreover, inter-
vention analysis can be used to demonstrate the effect that
generic entry has on the utilization of or expenditure on a
branded medication. We ﬁnd that the drugs studied are affected
differently by this type of event.
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OBJECTIVES: To analyze, from a payer perspective, the net
beneﬁt of prescribing divalproex sodium extended-release
(DVPX-ER) versus valproic acid (VPA) in patients who suffer
from bipolar disorder. METHODS: The study used a decision
analytic framework to compare the net beneﬁt of DVPX-ER rel-
ative to VPA in the treatment of bipolar disease. The decision
model incorporated on two primary outcomes: GI side effects,
and treatment success. Levels of health service utilization and
probability values were obtained from an expert panel comprised
of 15 psychiatrists. Costs were obtained from an academic
medical center. Two-way sensitivity analysis on the probability
of GI events and the probability of disease control for VPA was
used to provide further insight regarding the set of combinations
of values in the model consistent with the decision to use VPA
and DVPX-ER. RESULTS: The average probability of GI side
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effects associated with VPA and DVPX-ER estimated by the
expert panel was 0.36 and 0.10 respectively. The average prob-
ability of treatment success for VPA and DVPX-ER was esti-
mated to be 0.45 and 0.58 respectively. In the base case analysis,
the expected total cost per patient was $33,525 and $24,968 for
VPA and DVPX-ER respectively, a difference of $8557 favoring
ER. The expert panel also estimated the frequency of drug
switching within one year for VPA and DVPX-ER to be 58.3%
and 28.7% for VPA and DVPX-ER respectively. Finally, sensi-
tivity analysis results indicated DVPX-ER was the preferred
option when the probability of disease control with VPA was 0.5
or less, across all GI event probabilities with VPA. CONCLU-
SION: The results from our decision analysis, based on proba-
bilities of major events and associated utilization from an expert
panel, suggest that divalproex sodium extended-release provides
greater net beneﬁt than valproic acid in the treatment of bipolar
disorder.
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OBJECTIVES: The aim of the study was to estimate the cost-
effectiveness relation of the long-acting injection formulation of
Risperidone (LARI) IM every 2 weeks vs oral antipsychotics
Olanzapine and Risperidone and the traditional prolonged-
action antipsychotic injection formulation of haloperidol depot
in the pharmacological management of schizophrenia in Mexico.
Consequently, a pharmacoeconomic study was proposed using a
cost-effectiveness model in adult patients treated in the Mexican
Social Security Institute (IMSS). METHODS: A decision analy-
sis was developed using a retrospective and comparative cost-
effectiveness model over a 24 month period. A sample of
Schizophrenic patients was obtained using IMSS databases and
a decision tree based on relapses, hospitalization, pharmacolog-
ical treatment, hospital discharges and re-hospitalizations. To
determine the criteria for the effectiveness of each alternative, a
meta-analysis was carried out based on national and interna-
tional literature taking the clinical outcomes: total PANSS,
changes in body weight, AE, adherence, hospitalization, re-hos-
pitalization and relapses. The factors for costs were: speciﬁc
pharmacological therapy, outpatient consultations for treatment,
basal hospitalization, re-hospitalization, length of hospital stay
and absence from work. The decision tree was validated by a
panel of experts. RESULTS: Risperidone LA was the alternative
with the lowest cost for annual treatment ($84,877 pesos). Dif-
ferences versus the other treatment therapies were found in
regards to hospitalization, subsequent hospitalizations and, to a
lesser degree, absenteeism from work. Treatment with LARI pro-
duced savings of $8324 pesos compared to Haloperidol Depot
(the most widely used injected antipsychotic in Mexico); com-
pared to the second generation antipsychotics (atypical), savings
were $27,733 pesos versus Olanzapine and $1875 pesos versus
oral Risperidone. LARI produced the lowest number of re-hos-
pitalized patients and events requiring re-hospitalization as well
as superior clinical improvements compared to the other thera-
pies. CONCLUSION: The study demonstrated that LARI is a
cost-efﬁcient and dominant alternative for the treatment of schiz-
ophrenia patients in Mexico.
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OBJECTIVES: The objective of this study was to determine the
medication use patterns and costs associated with atypical
antipsychotics in the treatment of bipolar disorder. METHODS:
Data for this retrospective study were obtained from private
payer administrative claims. Bipolar patients were identiﬁed
based on one inpatient or two outpatient diagnoses of bipolar
disorder. Those who initiated on olanzapine, risperidone, queti-
apine, or ziprasidone during 2003, had not used the initiated
medication during the prior three-months, and met eligibility cri-
teria in prior six-months and post one-year were included.
RESULTS: Among the 1516 bipolar patients in this study, olan-
zapine (N = 507) was more likely to be initiated as the primary
bipolar medication (50.9%) than risperidone (39.9%, N = 424),
quetiapine (36.1%, N = 463) or ziprasidone (25.4%, N = 122).
During the post one-year, olanzapine was used as the only
primary bipolar medication for more days (73.5) than risperi-
done (53.7), quetiapine (56.3), and ziprasidone (36.6). Overall,
olanzapine and risperidone initiated patients incurred lower total
annual costs ($15,208 & $14,216 respectively) than quetiapine
($18,087)and ziprasidone ($18,729) initiated patients. CON-
CLUSION: Among the atypical antipsychotics studied, olanzap-
ine was used more often as a primary bipolar medication while
quetiapine and ziprasidone were used more in conjunction with
other bipolar medication for bipolar disorder.
PMH12
DEPRESSED INDIVIDUALS WITH MUSCULOSKELETAL
CHRONIC PAIN AND HEADACHE SHOW HIGHER HEALTH
CARE UTILIZATION AND COSTS
Iyer RG, Fensterheim LE, Berger JE, Dodds MM,Weston NK
Caremark Inc, Northbrook, IL, USA
OBJECTIVES: To compare resource utilization in depressed
patients with and without co-morbid musculoskeletal chronic
pain (MSCP) and headache. METHODS: Caremark administra-
tive pharmacy and medical claims data were analyzed in this
study over a one-year period. ICD9 CM codes were used to iden-
tify participants with depression, MSCP and headache. Out-
comes included number of visits and expenditures associated
with ofﬁce visits (MD), emergency room visits (ER), hospital-
izations (HOS) using medical claims data, and prescription costs
(Rx) using pharmacy claims data. Logistic regression was used
to identify the demographic predictors of co-morbid MSCP and
headache in patients with depression. Analysis of covariance was
used to determine differences in health care use and expendi-
tures, adjusting for age, sex, and marital status. RESULTS: One-
year prevalence of MSCP and headache in depressed patients was
18%. Women with depression were 1.7 times more likely to have
MSCP or headache than men with depression (p < 0.0001). After
adjusting for age, sex and marital status, depressed patients with
MSCP and headache had signiﬁcantly more ER visits per year
(2.5 vs. 1.6, p < 0.0001) and physician visits per year (10.0 vs.
7.0, P < 0.0001). Annual ER, MD and Rx expenditures were sig-
niﬁcantly higher in the depression group with co-morbid MSCP
and headache (ER: $2008 vs. $1635, p < 0.0001 and MD: $559
vs. $412, p < 0.00001 and Rx: $3926 vs. $3111, p < 0.0001).
CONCLUSION: Depressed patients with co-morbid MSCP and
headache utilize more health care resources and incur higher
health care expenditures. Treating depression and pain in com-
bination could improve ﬁnancial and clinical outcomes.
